Pharmacokinetic (PK) exposure parameters of lumefantrine 28 days [clinicaltrials_resource:98a9c2e2db00aaca51e5ff3be5264bab]
Sparse pharmacokinetic data will be pooled for evaluation of both individual and population PK parameter estimates of lumefantrine using Non linear mixed effect model. Pharmacokinetic exposure will be depicted principally by area under the concentration-time curves following the last dose through to 28 days of follow up (AUC0-28). Other PK parameters portraying exposure will also be assessed alongside. These include half life (t1/2), peak concentrations (Cmax) and time to reach Cmax (Tmax), apparent clearance and volumes of distribution.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Pharmacokinetic (PK) exposure parameters of lumefantrine 28 days [clinicaltrials_resource:98a9c2e2db00aaca51e5ff3be5264bab]
Sparse pharmacokinetic data will be pooled for evaluation of both individual and population PK parameter estimates of lumefantrine using Non linear mixed effect model. Pharmacokinetic exposure will be depicted principally by area under the concentration-time curves following the last dose through to 28 days of follow up (AUC0-28). Other PK parameters portraying exposure will also be assessed alongside. These include half life (t1/2), peak concentrations (Cmax) and time to reach Cmax (Tmax), apparent clearance and volumes of distribution.
Bio2RDF identifier
98a9c2e2db00aaca51e5ff3be5264bab
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:98a9c2e2db00aaca51e5ff3be5264bab
measure [clinicaltrials_vocabulary:measure]
Pharmacokinetic (PK) exposure parameters of lumefantrine
time frame [clinicaltrials_vocabulary:time-frame]
description
Sparse pharmacokinetic data wi ...... e and volumes of distribution.
identifier
clinicaltrials_resource:98a9c2e2db00aaca51e5ff3be5264bab
title
Pharmacokinetic (PK) exposure parameters of lumefantrine 28 days
@en
type
label
Pharmacokinetic (PK) exposure ...... 9c2e2db00aaca51e5ff3be5264bab]
@en